Imunon (NASDAQ:IMNN) Receives Buy Rating from D. Boral Capital

Imunon (NASDAQ:IMNN)‘s stock had its “buy” rating restated by equities research analysts at D. Boral Capital in a research note issued on Wednesday,Benzinga reports. They presently have a $29.00 price objective on the stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of Imunon in a research report on Thursday, December 19th.

Imunon Stock Down 1.5 %

Shares of IMNN stock opened at $0.87 on Wednesday. The stock’s fifty day simple moving average is $0.89 and its 200 day simple moving average is $0.96. Imunon has a twelve month low of $0.52 and a twelve month high of $3.65. The firm has a market capitalization of $12.64 million, a P/E ratio of -0.46 and a beta of 2.03.

Institutional Investors Weigh In On Imunon

A hedge fund recently raised its stake in Imunon stock. Geode Capital Management LLC increased its stake in Imunon, Inc. (NASDAQ:IMNN) by 10.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 139,505 shares of the company’s stock after acquiring an additional 13,570 shares during the quarter. Geode Capital Management LLC owned about 0.96% of Imunon worth $133,000 at the end of the most recent reporting period. 4.47% of the stock is currently owned by hedge funds and other institutional investors.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.